CDC COVID-19 Response, Post-COVID Conditions Team, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA; Chronic Viral Diseases Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging Zoonotic and Infectious Diseases, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA.
CDC COVID-19 Response, Post-COVID Conditions Team, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, 1600 Clifton Road NE, Mailstop US10-1, Atlanta, GA, 30329-4027, USA.
Disabil Health J. 2023 Apr;16(2):101436. doi: 10.1016/j.dhjo.2022.101436. Epub 2022 Dec 19.
Adults with disabilities are at increased risk for SARS-CoV-2 infection and severe disease; whether adults with disabilities are at an increased risk for ongoing symptoms after acute SARS-CoV-2 infection is unknown.
To estimate the frequency and duration of long-term symptoms (>4 weeks) and health care utilization among adults with and without disabilities who self-report positive or negative SARS-CoV-2 test results.
Data from a nationwide survey of 4510 U.S. adults administered from September 24, 2021-October 7, 2021, were analyzed for 3251 (79%) participants who self-reported disability status, symptom(s), and SARS-CoV-2 test results (a positive test or only negative tests). Multivariable models were used to estimate the odds of having ≥1 COVID-19-like symptom(s) lasting >4 weeks by test result and disability status, weighted and adjusted for socio-demographics.
Respondents who tested positive for SARS-CoV-2 had higher odds of reporting ≥1 long-term symptom (with disability: aOR = 4.50 [95% CI: 2.37, 8.54] and without disability: aOR = 9.88 [95% CI: 7.13, 13.71]) compared to respondents testing negative. Among respondents who tested positive, those with disabilities were not significantly more likely to experience long-term symptoms compared to respondents without disabilities (aOR = 1.65 [95% CI: 0.78, 3.50]). Health care utilization for reported symptoms was higher among respondents with disabilities who tested positive (40%) than among respondents without disabilities who tested positive (18%).
Ongoing symptoms among adults with and without disabilities who also test positive for SARS-CoV-2 are common; however, the frequency of health care utilization for ongoing symptoms is two-fold among adults with disabilities.
残疾成年人感染严重急性呼吸综合征冠状病毒 2 型（SARS-CoV-2）和出现严重疾病的风险增加；残疾成年人在急性 SARS-CoV-2 感染后是否有持续症状的风险增加尚不清楚。
估计自我报告 SARS-CoV-2 检测结果阳性或阴性的残疾和非残疾成年人中，长期症状（>4 周）的发生频率和持续时间以及卫生保健利用情况。
对 2021 年 9 月 24 日至 2021 年 10 月 7 日期间进行的一项全美 4510 名成年人调查的数据进行了分析，该调查包括 3251 名（79%）自我报告残疾状况、症状和 SARS-CoV-2 检测结果（阳性检测或仅阴性检测）的参与者。使用多变量模型，根据检测结果和残疾状况，估计有≥1 种 COVID-19 样症状持续>4 周的可能性，加权并调整了社会人口统计学因素。
SARS-CoV-2 检测呈阳性的受访者报告出现≥1 种长期症状的可能性更高（有残疾：调整比值比[aOR] = 4.50[95%置信区间：2.37，8.54]；无残疾：aOR = 9.88[95% CI：7.13，13.71]），与检测结果阴性的受访者相比。在检测结果阳性的受访者中，有残疾的受访者出现长期症状的可能性与无残疾的受访者相比没有显著差异（aOR = 1.65[95% CI：0.78，3.50]）。报告症状的残疾受访者比非残疾受访者更有可能利用卫生保健服务（40%比 18%）。
SARS-CoV-2 检测呈阳性的残疾和非残疾成年人中，持续症状较为常见；然而，残疾成年人持续症状的卫生保健利用率是无残疾成年人的两倍。
